Eli Lilly Stock Jumps, Biogen Drops on Alzheimer's Treatment Approval

The Wall Street Journal2021-06-24

(Update: June 24, 2021 at 09:32 a.m. ET)

Eli Lilly shares jumped over 8% in morning trading after the drug maker said it received breakthrough therapy designation for its Alzheimer's treatment from the Food and Drug Administration.

The move is meant to expedite the development and review of the experimental treatment.

Rival Biogen, whose own drug was approved earlier this month, fell over 6% in premarket trading. The FDA has faced criticism from some doctors and scientists for approving that drug.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
25